Top

Journal of Assisted Reproduction and Genetics

Published in:

01-11-2015 | Genetics

Evidence of an age-related correlation of ovarian reserve and FMR1 repeat number among women with “normal” CGG repeat status

Authors: Stephanie L. F. Gustin, Victoria Y. Ding, Manisha Desai, Benjamin Leader, Valerie L. Baker

Published in: Journal of Assisted Reproduction and Genetics | Issue 11/2015

Abstract

Purpose

The objective of this analysis is to examine the relationship between Fragile X Mental Retardation 1 gene (FMR1) cytosine-guanine-guanine (CGG) repeat number and ovarian reserve, with a particular focus exclusively on the range of CGG repeat number below the premutation (PM) range (<55 CGG repeats).

Methods

Our study included female patients who underwent assessment of FMR1 CGG repeat number and serum anti-Mullerian hormone (AMH) in 2009–2014. To examine the association between FMR1 repeat number and serum AMH, we created three summary measures of CGG repeat number for the two alleles—“Sum,” “Max,” and “Gap” (absolute difference). Using multivariable regression models, controlling for age, we then analyzed the impact of these summary measures on AMH.

Results

A total of 566 patients were included in our study. Using multivariable regression models, we found that the relationship between CGG repeat number and AMH differed depending on age. Specifically, in younger women, AMH increased by 7–8 % (Sum p < 0.01, Max p = 0.04) for every 1 unit increase in CGG repeat number. In contrast, starting at age 40, there was a 3 to 5 % decline in AMH for every 1 unit increase in CGG repeat number (Sum p < 0.01, Max p = 0.04).

Conclusions

This is the first study to report a statistically significant correlation of ovarian reserve and CGG repeat number in women with <55 CGG repeats. Although these women are generally considered to have a normal phenotype, our data suggest that increasing CGG repeat number within this normal range is associated with a more rapid decline in ovarian reserve.

Available only for authorised users

Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011;29(4):299–307. doi:10.1055/s-0031-1280915.CrossRefPubMed

ACOG. Committee opinion no. 469: carrier screening for fragile X syndrome. Obstet Gynecol. 2010;116(4):1008–10. doi:10.1097/AOG.0b013e3181fae884.CrossRef

Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005;117(4):376–82. doi:10.1007/s00439-005-1326-8.CrossRefPubMed

Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005;20(2):402–12. doi:10.1093/humrep/deh635.CrossRefPubMed

Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden JJ, Yang KT, Lee C, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study—preliminary data. Am J Med Genet. 1999;83(4):322–5.PubMedCentralCrossRefPubMed

Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97(3):189–94. doi:10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J.CrossRefPubMed

Karimov CB, Moragianni VA, Cronister A, Srouji S, Petrozza J, Racowsky C, et al. Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum Reprod. 2011;26(8):2077–83. doi:10.1093/humrep/der168.CrossRefPubMed

Bodega B, Bione S, Dalpra L, Toniolo D, Ornaghi F, Vegetti W, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod. 2006;21(4):952–7. doi:10.1093/humrep/dei432.CrossRefPubMed

Pastore LM, Young SL, Baker VL, Karns LB, Williams CD, Silverman LM. Elevated prevalence of 35–44 FMR1 trinucleotide repeats in women with diminished ovarian reserve. Reprod Sci. 2012;19(11):1226–31. doi:10.1177/1933719112446074.PubMedCentralCrossRefPubMed

10.

Gleicher N, Barad DH. The FMR1 gene as regulator of ovarian recruitment and ovarian reserve. Obstet Gynecol Surv. 2010;65(8):523–30. doi:10.1097/OGX.0b013e3181f8bdda.CrossRefPubMed

11.

Kline JK, Kinney AM, Levin B, Brown SA, Hadd AG, Warburton D. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause. 2014;21(7):740–8. doi:10.1097/GME.0000000000000139.PubMedCentralCrossRefPubMed

12.

Voorhuis M, Onland-Moret NC, Janse F, Ploos van Amstel HK, Goverde AJ, Lambalk CB. The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency. Hum Reprod. 2014;29(7):1585–93. doi:10.1093/humrep/deu095.CrossRefPubMed

13.

Riggs RM, Duran EH, Baker MW, Kimble TD, Hobeika E, Yin L. Assessment of ovarian reserve with anti-Mullerian hormone: a comparison of the predictive value of anti-Mullerian hormone, follicle-stimulating hormone, inhibin B, and age. Am J Obstet Gynecol. 2008;199(2):202 e1–8. doi:10.1016/j.ajog.2008.05.004.CrossRef

14.

Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011;95(2):747–50. doi:10.1016/j.fertnstert.2010.10.011.CrossRefPubMed

15.

Dolleman M, Faddy MJ, van Disseldorp J, van der Schouw YT, Messow CM, Leader B, et al. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metabolism. 2013;98(5):1946–53. doi:10.1210/jc.2012-4228.CrossRef

16.

Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med : Off J Am College Med Genet. 2005;7(8):584–7. doi: 10.109701.GIM.0000182468.22666.dd.

17.

Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Europ J Human Genet : EJHG. 2008;16(6):666–72. doi:10.1038/ejhg.2008.61.CrossRef

18.

Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, Rebar RW, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007;87(3):456–65. doi:10.1016/j.fertnstert.2006.09.004.CrossRefPubMed

19.

Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncla M, Badenas C, Kulisevsky J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Europ J Human Genet : EJHG. 2009;17(10):1359–62. doi:10.1038/ejhg.2009.51.CrossRef

20.

Leader B, Baker VL. Maximizing the clinical utility of antimullerian hormone testing in women’s health. Curr Opin Obstetrics Gynecol. 2014;26(4):226–36. doi:10.1097/GCO.0000000000000087.CrossRef

21.

Lie Fong S, Visser JA, Welt CK, de Rijke YB, Eijkemans MJ, Broekmans FJ, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metabolism. 2012;97(12):4650–5. doi:10.1210/jc.2012-1440.CrossRef

22.

Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024. doi:10.1371/journal.pone.0022024.PubMedCentralCrossRefPubMed

23.

De Geyter C, M’Rabet N, De Geyter J, Zurcher S, Moffat R, Bosch N, et al. Similar prevalence of expanded CGG repeat lengths in the fragile X mental retardation I gene among infertile women and among women with proven fertility: a prospective study. Genet Med : Off J Am College Med Genet. 2014;16(5):374–8. doi:10.1038/gim.2013.146.CrossRef

24.

Barasoain M, Barrenetxea G, Huerta I, Telez M, Carrillo A, Perez C, et al. Study of FMR1 gene association with ovarian dysfunction in a sample from the Basque Country. Gene. 2013;521(1):145–9. doi:10.1016/j.gene.2013.03.032.CrossRefPubMed

25.

Murray A, Schoemaker MJ, Bennett CE, Ennis S, Macpherson JN, Jones M, et al. Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Genet Med : Off J Am College Med Genet. 2014;16(1):19–24. doi:10.1038/gim.2013.64.CrossRef

26.

Pastore LM, Johnson J. The FMR1 gene, infertility, and reproductive decision-making: a review. Front Genet. 2014;5:195. doi:10.3389/fgene.2014.00195.PubMedCentralCrossRefPubMed

27.

Kline JK, Kinney AM, Levin B, Brown SA, Hadd AG, Warburton D. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause. 2014. doi:10.1097/GME.0000000000000139. PubMed.PubMedCentralPubMed

28.

Choe SA, Kim KC, Lee JY, Kim CH, Hwang D, Jee BC. The relationship between the number of CGG repeats and serum level of anti-Mullerian hormone in women without FMR1 premutation. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):275–8. doi:10.1016/j.ejogrb.2013.05.002.CrossRefPubMed

29.

Gleicher N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet Gynecol Scand. 2009;88(9):1024–30. doi:10.1080/00016340903171058.CrossRefPubMed

Title: Evidence of an age-related correlation of ovarian reserve and FMR1 repeat number among women with “normal” CGG repeat status
Authors: Stephanie L. F. Gustin
Victoria Y. Ding
Manisha Desai
Benjamin Leader
Valerie L. Baker
Publication date: 01-11-2015
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 11/2015
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-015-0577-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evidence of an age-related correlation of ovarian reserve and FMR1 repeat number among women with “normal” CGG repeat status

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2015

Macrozoospermia: screening for the homozygous c.144delC mutation in AURKC gene in infertile men and estimation of its heterozygosity frequency in the Tunisian population

Diagnosis of abnormal human fertilization status based on pronuclear origin and/or centrosome number

An increase in IL-1β concentrations in embryo culture-conditioned media obtained by in vitro fertilization on day 3 is related to successful implantation

A single-cell assay for telomere DNA content shows increasing telomere length heterogeneity, as well as increasing mean telomere length in human spermatozoa with advancing age

Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility

Case reports to suggest an algorithm for management of total fertilisation failure prior to use of donor gametes